XtalPi

Headlines · 4

1. Oct 23
   Verdine weighs AI’s drug-discovery value against capital pressure on biotech

   In a Huxiu interview, Harvard professor Gregory L. Verdine said AI benefits drug discovery by changing researchers’ work rather than replacing them. He also argued that AI offers faster and larger returns, while biotech lacks scale effects, making it harder for biotechnology to compete for venture investment. Verdine said Chinese innovation-drug companies remain focused mainly on best-in-class assets and need more long-term investment in novel targets. Tsinghua University pharmacy dean Qian Feng said overseas licensing has become a financing route for Chinese biotech companies struggling to raise capital domestically.

   虎嗅 AI · 🔥 0
2. Oct 19
   AI drug discovery pivots toward digital twins and virtual cells

   A Huxiu AI reprint of a Shenlan Guan article reports that this autumn the AI drug discovery field's attention is shifting from molecule generation toward digital twins and virtual cells, with practitioners saying the direction has been repeatedly raised since summer and that many AIDD companies now describe plans to move into virtual cells. The report says that in early October Mark Zuckerberg's Biohub expanded its virtual biology program to $1.8 billion, working with the US Department of Energy, NIH and Google DeepMind to build public data infrastructure for virtual cell models, and that nearly 10 related funding deals have appeared in China since April 2026. It also lists bottlenecks: calibrated dynamic time-series quantitative single-cell data is scarce, single-cell sequencing yields only snapshots, and models struggle to pass wet-lab validation of extrapolation and drug-perturbation prediction; virtual clinical trials and digital-twin diagnostics also lack mature regulatory and review standards, and the business model remains unclear.

   虎嗅 AI · 🔥 0
3. Oct 10
   AI drug design is flooding Chinese labs with wet-lab work

   Anthropic's Claude designed 1,320 binding proteins against a dozen targets, which Adaptyv Bio and Twist synthesized and tested; 354 were confirmed to bind, a hit rate near 30% versus the traditional 10%–15%. The article argues that as AI pushes the marginal cost of molecular design toward zero, the first orders flow to lab-service providers: GenScript's AIDD revenue doubled year over year in H1 with gross margins about 20 points above its traditional protein-expression business, while XtalPi posted 803 million yuan in 2025 revenue, tripled and its first full-year profit. Meanwhile Washington is trying to pull early-stage R&D and clinical capacity back onshore via HHS's TrialBlazer plan and the BIOSECURE Act.

   MIT科技评论中文 · 🔥 0
4. Oct 7
   XtalPi details Kodexia closed-loop AI platform for siRNA drug discovery

   XtalPi outlined Kodexia, its closed-loop platform that combines generative AI, biological modeling and automated experiments to speed siRNA therapy discovery, and highlighted six proprietary preclinical programs spanning metabolic, renal, respiratory and central nervous system diseases, more than half of which have completed animal efficacy testing. At its core is XtalPi's siFormer architecture; the company says internal preclinical benchmarking showed molecular design efficiency nearly three times that of conventional workflows, and that over 50% of first-round designs across multiple programs showed stronger in vivo activity than positive controls. XtalPi also says its lead IgA nephropathy program reached non-human primate efficacy data in seven months with greater activity and durability than a clinical-stage reference molecule — all company-reported figures.

   TechRepublic · 🔥 0

Experience and discussion from the community

Share my XtalPi experienceAsk about XtalPi